Boston Scientific (NYSE:BSX) Sets New 1-Year Low - Here's Why

Key Points

• Boston Scientific hit a new 52-week low, with shares trading as low as $53.26, extending a sharp decline from its recent close of $53.93.
• Despite the weak stock performance, the company’s latest quarterly results beat estimates, with EPS of $0.80 and revenue of $5.20 billion, both slightly above analyst expectations.
• Analysts remain mostly positive overall, but several have cut price targets recently; the consensus rating is still Moderate Buy with an average target price of $93.91.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $53.26 and last traded at $53.3350, with a volume of 643182 shares changing hands. The stock had previously closed at $53.93.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Weiss Ratings cut Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a report on Wednesday, February 4th. National Bank Financial set a $115.00 price target on Boston Scientific in a report on Monday, February 2nd. Raymond James Financial reiterated an "outperform" rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Citigroup reduced their price target on Boston Scientific from $94.00 to $87.00 and set a "buy" rating for the company in a report on Tuesday, April 7th. Finally, Mizuho reduced their price target on Boston Scientific from $115.00 to $90.00 and set an "outperform" rating for the company in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $93.91.

Boston Scientific Stock Performance

The firm has a market cap of $79.46 billion, a PE ratio of 22.35, a PEG ratio of 0.99 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The firm's 50 day simple moving average is $65.95 and its 200 day simple moving average is $83.68.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts' expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business's quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Institutional Trading of Boston Scientific

A number of large investors have recently made changes to their positions in BSX. Murphy & Mullick Capital Management Corp grew its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter valued at about $26,000. Swiss RE Ltd. bought a new position in Boston Scientific during the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific during the 4th quarter valued at about $26,000. Finally, United Community Bank grew its holdings in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 147 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.